How should an acute COPD exacerbation be managed, including bronchodilator regimen, systemic corticosteroid dosing, antibiotic use when infection is suspected, oxygen therapy targets, and criteria for outpatient versus inpatient care?

Management of Acute COPD Exacerbation

For an acute COPD exacerbation, immediately initiate combined short-acting bronchodilators (salbutamol 2.5–5 mg plus ipratropium 0.25–0.5 mg via nebulizer every 4–6 hours), oral prednisone 30–40 mg daily for exactly 5 days, controlled oxygen targeting SpO₂ 88–92%, and antibiotics for 5–7 days when sputum purulence is present with either increased dyspnea or sputum volume; use non-invasive ventilation as first-line for acute hypercapnic respiratory failure. 1

Immediate Bronchodilator Therapy

• Administer combined nebulized salbutamol 2.5–5 mg plus ipratropium 0.25–0.5 mg every 4–6 hours during the acute phase, as this combination provides superior bronchodilation lasting 4–6 hours compared with either agent alone. 1

• Nebulizers are preferred over metered-dose inhalers in hospitalized patients with moderate-to-severe exacerbations because they eliminate the need for coordinated high-frequency inhalations and are easier for dyspneic patients to use. 1

• Continue regular nebulized treatments every 4–6 hours for 24–48 hours or until clinical improvement occurs, then transition to metered-dose inhalers with spacer. 1

• Avoid intravenous methylxanthines (theophylline or aminophylline) entirely, as they increase adverse effects without delivering clinical benefit. 1, 2

Systemic Corticosteroid Protocol

• Give oral prednisone 30–40 mg once daily for exactly 5 days starting immediately; this short course is as effective as a 14-day regimen while reducing cumulative steroid exposure by more than 50%. 1, 2

• Oral administration is equivalent to intravenous delivery and should be the default route unless the patient cannot tolerate oral intake due to vomiting, inability to swallow, or impaired gastrointestinal function. 1, 2

• The 5-day regimen improves lung function and oxygenation, shortens recovery time and hospital stay, reduces treatment failure by over 50%, and lowers the risk of rehospitalization within 30 days. 1, 2, 3

• Do not extend systemic corticosteroids beyond 5–7 days for a single exacerbation unless another indication exists, as longer courses increase adverse effects (hyperglycemia, weight gain, insomnia, infection risk) without additional benefit. 1, 2

• No tapering is required after a 5-day course; simply stop the medication after day 5. 2

• If intravenous administration is necessary, use methylprednisolone 40 mg IV every 6–8 hours (equivalent to prednisone 30–40 mg orally daily) or hydrocortisone 100 mg IV. 2

Antibiotic Therapy

• Prescribe antibiotics for 5–7 days when sputum purulence is present together with either increased dyspnea or increased sputum volume (two of three cardinal symptoms, with purulence required). 1, 4

• This strategy reduces short-term mortality by approximately 77%, treatment failure by 53%, and sputum purulence by 44%. 1

• First-line agents (selected according to local resistance patterns) include amoxicillin-clavulanate 875/125 mg twice daily, doxycycline 100 mg twice daily, or azithromycin (500 mg day 1, then 250 mg daily for 4 days). 1, 4

• The most common causative organisms are Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. 1

• Do not prescribe antibiotics routinely; limit use to cases meeting the purulent-sputum plus one additional cardinal symptom criterion. 1

Oxygen Therapy

• Target SpO₂ 88–92% using controlled-delivery devices (Venturi mask 24–28% FiO₂ or nasal cannula 1–2 L/min) to correct life-threatening hypoxemia while minimizing CO₂ retention and respiratory acidosis. 1, 4

• Obtain an arterial blood gas within 60 minutes of initiating oxygen to identify hypercapnia (PaCO₂ > 45 mmHg) or acidosis (pH < 7.35). 1

• If the patient deteriorates clinically or the initial pH is < 7.35, repeat the arterial blood gas 30–60 minutes later. 1

• High-flow oxygen (>28% FiO₂ or >4 L/min) delivered without concurrent blood-gas monitoring worsens hypercapnic respiratory failure and increases mortality by approximately 78%. 1

• When the initial ABG shows normal pH and PaCO₂, the saturation target may be increased to 94–98% only if the patient has no prior hypercapnic failure requiring NIV and their usual stable saturation is ≥94%. 1

Non-Invasive Ventilation (NIV)

• Initiate NIV immediately as first-line therapy when acute hypercapnic respiratory failure (PaCO₂ > 45 mmHg) with acidosis (pH < 7.35) persists for more than 30 minutes after standard medical treatment. 1, 4

• NIV improves gas exchange, reduces work of breathing, decreases intubation rates by approximately 50%, shortens hospital stay, and improves survival; success rates in appropriately selected patients are 80–85%. 1, 5

• Transfer to ICU if pH remains < 7.26 despite NIV. 1

• Contraindications to NIV include altered mental status with inability to protect the airway, large-volume secretions, hemodynamic instability, or recent facial/upper-airway surgery. 1

Hospitalization Criteria

Admit or evaluate in the emergency department if any of the following are present:

• Marked increase in dyspnea unresponsive to outpatient therapy 1
• Respiratory rate > 30 breaths/min 1
• Inability to eat or sleep because of respiratory symptoms 1
• New or worsening hypoxemia (SpO₂ < 90% on room air) 1
• New or worsening hypercapnia (PaCO₂ > 45 mmHg) 1
• Altered mental status or loss of alertness 1
• Persistent rhonchi after initial treatment requiring continued nebulization 1
• High-risk comorbidities (pneumonia, cardiac arrhythmia, heart failure, diabetes, renal or liver failure) 1
• Inability to care for self at home 1

Outpatient Management

• More than 80% of exacerbations can be managed on an outpatient basis. 1

• For mild exacerbations, short-acting bronchodilators alone may be sufficient. 1, 4

• For moderate exacerbations, use short-acting bronchodilators plus oral corticosteroids (prednisone 30–40 mg daily for 5 days) and antibiotics when indicated. 1, 4

• Schedule follow-up within 3–7 days to assess treatment response. 1

Discharge Planning and Follow-Up

• Arrange pulmonary rehabilitation within 3 weeks after discharge to reduce readmissions and improve quality of life; initiating rehabilitation during the hospital stay is associated with increased mortality. 1

• Optimize long-acting bronchodilator therapy (LAMA, LABA, or combinations) before discharge. 1

• Do not step down from triple therapy (LAMA + LABA + ICS) during or immediately after an exacerbation, as inhaled corticosteroid withdrawal raises the risk of recurrent exacerbations. 1

• Verify proper inhaler technique with the patient at discharge. 1

• Provide smoking cessation counseling with nicotine replacement therapy and behavioral support for current smokers. 1

Common Pitfalls to Avoid

• Never power nebulizers with oxygen in hypercapnic patients; use compressed air and provide supplemental oxygen via a separate nasal cannula. 1

• Never delay NIV when criteria for acute hypercapnic respiratory failure are met (pH < 7.35, PaCO₂ > 45 mmHg persisting >30 minutes). 1

• Never use methylxanthines (theophylline/aminophylline) in acute exacerbations—they add toxicity without benefit. 1, 2

• Never continue systemic corticosteroids beyond 5–7 days for a single exacerbation unless another indication exists. 1, 2

• Never administer high-flow oxygen without arterial blood-gas monitoring, as this can worsen hypercapnic respiratory failure and increase mortality. 1